These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 36653070)

  • 1. Novel banana lectin CAR-T cells to target pancreatic tumors and tumor-associated stroma.
    McKenna MK; Ozcan A; Brenner D; Watanabe N; Legendre M; Thomas DG; Ashwood C; Cummings RD; Bonifant C; Markovitz DM; Brenner MK
    J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36653070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glycoprotein Targeted CAR-NK Cells for the Treatment of SARS-CoV-2 Infection.
    Christodoulou I; Rahnama R; Ravich JW; Seo J; Zolov SN; Marple AN; Markovitz DM; Bonifant CL
    Front Immunol; 2021; 12():763460. PubMed ID: 35003077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mesothelin CAR T Cells Secreting Anti-FAP/Anti-CD3 Molecules Efficiently Target Pancreatic Adenocarcinoma and its Stroma.
    Wehrli M; Guinn S; Birocchi F; Kuo A; Sun Y; Larson RC; Almazan AJ; Scarfò I; Bouffard AA; Bailey SR; Anekal PV; Montero Llopis P; Nieman LT; Song Y; Xu KH; Berger TR; Kann MC; Leick MB; Silva H; Salas-Benito D; Kienka T; Grauwet K; Armstrong TD; Zhang R; Zhu Q; Fu J; Schmidts A; Korell F; Jan M; Choi BD; Liss AS; Boland GM; Ting DT; Burkhart RA; Jenkins RW; Zheng L; Jaffee EM; Zimmerman JW; Maus MV
    Clin Cancer Res; 2024 May; 30(9):1859-1877. PubMed ID: 38393682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Research progress and design optimization of CAR-T therapy for pancreatic ductal adenocarcinoma.
    Li T; Li H; Li S; Xu S; Zhang W; Gao H; Xu H; Wu C; Wang W; Yu X; Liu L
    Cancer Med; 2019 Sep; 8(11):5223-5231. PubMed ID: 31339230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Orthotopic and Heterotopic Murine Models of Pancreatic Cancer Exhibit Different Immunological Microenvironments and Different Responses to Immunotherapy.
    Wang J; Liu X; Ji J; Luo J; Zhao Y; Zhou X; Zheng J; Guo M; Liu Y
    Front Immunol; 2022; 13():863346. PubMed ID: 35874730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BCL6 overexpression in CD4
    Lin X; Dai Z; Tasiheng Y; Zhang R; Wang R; Dong J; Chen Y; Ma M; Zou X; Yan Y; Wang X; Yu X; Cheng H; Liu C
    Biochim Biophys Acta Mol Basis Dis; 2024 Oct; 1870(7):167346. PubMed ID: 38986820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinically relevant orthotopic pancreatic cancer models for adoptive T cell transfer therapy.
    Horvat NK; Karpovsky I; Phillips M; Wyatt MM; Hall MA; Herting CJ; Hammons J; Mahdi Z; Moffitt RA; Paulos CM; Lesinski GB
    J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38191243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Runx3-overexpression cooperates with ex vivo AKT inhibition to generate receptor-engineered T cells with better persistence, tumor-residency, and antitumor ability.
    Tang J; Sheng J; Zhang Q; Ji Y; Wang X; Zhang J; Wu J; Song J; Bai X; Liang T
    J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36849200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FAP-targeted CAR-T suppresses MDSCs recruitment to improve the antitumor efficacy of claudin18.2-targeted CAR-T against pancreatic cancer.
    Liu Y; Sun Y; Wang P; Li S; Dong Y; Zhou M; Shi B; Jiang H; Sun R; Li Z
    J Transl Med; 2023 Apr; 21(1):255. PubMed ID: 37046312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Novel Siglec-4 Derived Spacer Improves the Functionality of CAR T Cells Against Membrane-Proximal Epitopes.
    Schäfer D; Henze J; Pfeifer R; Schleicher A; Brauner J; Mockel-Tenbrinck N; Barth C; Gudert D; Al Rawashdeh W; Johnston ICD; Hardt O
    Front Immunol; 2020; 11():1704. PubMed ID: 32849600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the activated microenvironment with endosialin (CD248)-directed CAR-T cells ablates perivascular cells to impair tumor growth and metastasis.
    Ash SL; Orha R; Mole H; Dinesh-Kumar M; Lee SP; Turrell FK; Isacke CM
    J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38413223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proton radiation boosts the efficacy of mesothelin-targeting chimeric antigen receptor T cell therapy in pancreatic cancer.
    Amit U; Uslu U; Verginadis II; Kim MM; Motlagh SAO; Diffenderfer ES; Assenmacher CA; Bicher S; Atoche SJ; Ben-Josef E; Young RM; June CH; Koumenis C
    Proc Natl Acad Sci U S A; 2024 Jul; 121(31):e2403002121. PubMed ID: 39047033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activated pancreatic stellate cells sequester CD8+ T cells to reduce their infiltration of the juxtatumoral compartment of pancreatic ductal adenocarcinoma.
    Ene-Obong A; Clear AJ; Watt J; Wang J; Fatah R; Riches JC; Marshall JF; Chin-Aleong J; Chelala C; Gribben JG; Ramsay AG; Kocher HM
    Gastroenterology; 2013 Nov; 145(5):1121-32. PubMed ID: 23891972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-throughput method to analyze the cytotoxicity of CAR-T Cells in a 3D tumor spheroid model using image cytometry.
    Zurowski D; Patel S; Hui D; Ka M; Hernandez C; Love AC; Lin B; Moore A; Chan LL
    SLAS Discov; 2023 Apr; 28(3):65-72. PubMed ID: 36758833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual targeting chimeric antigen receptor cells enhance antitumour activity by overcoming T cell exhaustion in pancreatic cancer.
    Ruixin S; Yifan L; Yansha S; Min Z; Yiwei D; Xiaoli H; Bizhi S; Hua J; Zonghai L
    Br J Pharmacol; 2024 Nov; 181(22):4628-4646. PubMed ID: 39129178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generation of an in vitro 3D PDAC stroma rich spheroid model.
    Ware MJ; Keshishian V; Law JJ; Ho JC; Favela CA; Rees P; Smith B; Mohammad S; Hwang RF; Rajapakshe K; Coarfa C; Huang S; Edwards DP; Corr SJ; Godin B; Curley SA
    Biomaterials; 2016 Nov; 108():129-42. PubMed ID: 27627810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors.
    Parihar R; Rivas C; Huynh M; Omer B; Lapteva N; Metelitsa LS; Gottschalk SM; Rooney CM
    Cancer Immunol Res; 2019 Mar; 7(3):363-375. PubMed ID: 30651290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Armored TGFβRIIDN ROR1-CAR T cells reject solid tumors and resist suppression by constitutively-expressed and treatment-induced TGFβ1.
    Tran TM; Chand Thakuri BK; Nurmukhambetova S; Lee JJ; Hu P; Tran NQ; Steimle B; Dash P; Schneider D
    J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38609317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ectopic CXCR2 expression cells improve the anti-tumor efficiency of CAR-T cells and remodel the immune microenvironment of pancreatic ductal adenocarcinoma.
    Dai Z; Lin X; Wang X; Zou X; Yan Y; Wang R; Chen Y; Tasiheng Y; Ma M; Wang X; Cheng H; Yu X; Liu C
    Cancer Immunol Immunother; 2024 Mar; 73(4):61. PubMed ID: 38430267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of chimeric antigen receptor T cells against protease-activated receptor 1 for treating pancreatic cancer.
    Hung HC; Fan MH; Wang D; Miao CH; Su P; Liu CL
    BMC Med; 2023 Sep; 21(1):338. PubMed ID: 37667257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.